AFT Pharmaceuticals (NZSE:AFT) EBIT : NZ$18.9 Mil (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is AFT Pharmaceuticals EBIT?

AFT Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2023 was NZ$3.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was NZ$18.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. AFT Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2023 was 2.67%. AFT Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 12.48%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. AFT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 5.66%.

AFT Pharmaceuticals EBIT Historical Data

The historical data trend for AFT Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals EBIT Chart

AFT Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT

Get a 7-Day Free Trial

6.16

20.93

11.33

21.12

18.67

AFT Pharmaceuticals Semi-Annual Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EBIT	Get a 7-Day Free Trial											5.67	15.45	3.52	15.16	3.78

Competitive Comparison of AFT Pharmaceuticals's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AFT Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's EV-to-EBIT falls into.

AFT Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$18.9 Mil.

AFT Pharmaceuticals (NZSE:AFT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

AFT Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	3.384 * ( 1 - 7.72% )	/	( (113.595	+	120.549)	/ 2 )
=	3.1227552	/	117.072
=	2.67 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	148.063	-	29.719	-	( 4.749	-	max(0, 39.775	-	94.6	+	4.749	))
=	113.595

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	158.872	-	32.151	-	( 6.172	-	max(0, 48.345	-	95.124	+	6.172	))
=	120.549

Note: The Operating Income data used here is two times the semi-annual (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

AFT Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	7.564	/	( ( (3.365 + max(73.169, 0))	+	(4.098 + max(40.607, 0)) )	/	2 )
=	7.564	/	( ( 76.534	+	44.705 )	/	2 )
=	7.564	/	60.6195
=	12.48 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(59.682	+	42.397	+	7.836)	-	(29.719	+	0.834	+	6.193)
=	73.169

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(33.411	+	54.648	+	0.893)	-	(32.151	+	5.321	+	10.873)
=	40.607

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

AFT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	18.937	/	334.561
	=	5.66 %

AFT Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

AFT Pharmaceuticals (NZSE:AFT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (NZSE:AFT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

AFP:Australia

Address

129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622

Website

https://www.aftpharm.com

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.